Jonathan E. Rosenberg
Impact in
Papers in
- Co-authors
- Joaquim Bellmunt (74 shared papers)Daniel P. Petrylak (74 shared papers)Eric J. Small (30 shared papers)Toni K. Choueiri (48 shared papers)Dean F. Bajorin (123 shared papers)Guru Sonpavde (48 shared papers)Elisabeth I. Heath (18 shared papers)Brian I. Rini (10 shared papers)
- Journals
- Journal of Clinical Oncology (197 papers)Annals of Oncology (29 papers)Clinical Genitourinary Cancer (17 papers)Cancer (15 papers)The Journal of Urology (13 papers)
- Partner nations
- United StatesItalyFrance
In The Last Decade
Jonathan E. Rosenberg
395 papers receiving 13.6k citations
Jonathan E. Rosenberg's Hit Papers
Peers
Comparison fields: 5 of 127
- Surgery 6.6k
- Oncology 4.1k
- Cancer Research 1.6k
- Pulmonary and Respiratory Medicine 3.3k
- Urology 419
Countries citing papers authored by Jonathan E. Rosenberg
This map shows the geographic impact of Jonathan E. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan E. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan E. Rosenberg more than expected).
Fields of papers citing papers by Jonathan E. Rosenberg
This network shows the impact of papers produced by Jonathan E. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan E. Rosenberg. The network helps show where Jonathan E. Rosenberg may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan E. Rosenberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 408 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 709 |
| 2 | Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Hit paper breakdown → | 2008 | 707 |
| 3 | Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Hit paper breakdown → | 2017 | 629 |
| 4 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Hit paper breakdown → | 2016 | 517 |
| 5 | Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2019 | 450 |
| 6 | 2010 | 339 | |
| 7 | A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Hit paper breakdown → | 2013 | 334 |
| 8 | 2008 | 320 | |
| 9 | 2010 | 306 | |
| 10 | Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets Hit paper breakdown → | 2017 | 265 |
| 11 | 2011 | 235 | |
| 12 | 2016 | 235 | |
| 13 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 232 |
| 14 | 2011 | 228 | |
| 15 | 2017 | 217 | |
| 16 | 2009 | 205 | |
| 17 | 2017 | 190 | |
| 18 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 189 |
| 19 | 2014 | 187 | |
| 20 | 2019 | 180 |
About Jonathan E. Rosenberg
Jonathan E. Rosenberg is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research, having authored 408 papers that have together received 13.8k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (302 papers), Urinary and Genital Oncology Studies (114 papers), Cancer Immunotherapy and Biomarkers (96 papers), Multiple and Secondary Primary Cancers (38 papers), Renal cell carcinoma treatment (35 papers), Cancer Genomics and Diagnostics (30 papers), Epigenetics and DNA Methylation (25 papers) and Cancer Research and Treatments (25 papers). The work is most often cited by research in Surgery (6.6k citations), Oncology (4.1k citations), Cancer Research (1.6k citations), Pulmonary and Respiratory Medicine (3.3k citations) and Urology (419 citations). Jonathan E. Rosenberg has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Joaquim Bellmunt, Daniel P. Petrylak, Eric J. Small, Toni K. Choueiri, Dean F. Bajorin, Guru Sonpavde, Elisabeth I. Heath, Brian I. Rini, Bernard H. Bochner and Matthew D. Galsky. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Genitourinary Cancer, Cancer and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.